Bautista-Arredondo S, Cerecero-García D, Macías-González F, Barrientos-Gutiérrez T

Language: English
References: 15
Page: 78-84
PDF size: 345.09 Kb.

ABSTRACT

Objective. To assess the impact of a vaccination campaign that administered five different technologies in a middleincome country with one of the largest Covid-19 epidemics. Materials and methods. Using data from Mexico’s Epidemiological Surveillance System for Viral Respiratory Disease (Sisver) and the design of the vaccine policy in Mexico as a natural experiment, we applied difference-in-differences econometric methods to assess the strategy’s effectiveness on transmission, hospitalizations, and mortality rates among adults 60 to 64 years old in Mexico between April and June 2021. Results. We estimated average effectiveness levels of 60.9% against confirmed cases of Covid-19. Vaccination also decreased hospitalizations and deaths by 62.7 and 62.6%, respectively. After adjusting for vaccination coverage, we found an impact of 79.1, 80.9, and 81.3% reduction in new cases, hospitalizations, and deaths among the vaccinated. Conclusion. Despite the significant progress in our knowledge of Covid-19 vaccination effectiveness, the available evidence relies mostly on experiences from high-income countries. This study contributes to the scientific literature of Covid-19 vaccination effectiveness in a middle-income country with a multi-vaccine scheme.

REFERENCES

1. Jara A, Undurraga EA, González C, Paredes F, Fontecilla T, Jara G, et al.Effectiveness of an inactivated SARS-CoV-2 vaccine in Chile. N Engl J Med. 2021;385:875-84. http://doi.org/10.1056/NEJMoa2107715

2. Haas EJ, Angulo FJ, McLaughlin JM, Anis E, Singer SR, Khan F, et al. Impactand effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2infections and COVID-19 cases, hospitalisations, and deaths following anationwide vaccination campaign in Israel: an observational study usingnational surveillance data. Lancet. 2021;397(10287):1819-29. http://doi.org/10.1016/S0140-6736(21)00947-8

3. Lopez-Bernal J, Andrews N, Gower C, Robertson C, Stowe J, TessierE, et al. Effectiveness of the Pfizer-BioNTech and Oxford-AstraZenecavaccines on covid-19 related symptoms, hospital admissions, and mortalityin older adults in England: test negative case-control study. BMJ. 2021;373.https://doi.org/10.1136/bmj.n1088

4. World Health Organization. Landscape of observational studies on theeffectiveness of COVID-19 vaccination. WHO, 2023 [cited March 2023].Available from: https://www.who.int/publications/m/item/draft-landscape-ofobservational-study-designs-on-the-effectiveness-of-covid-19-vaccination

5. Skowronski DM, Setayeshgar S, Zou M, Prystajecky N, Tyson JR,Sbihi H, et al. Comparative single-dose mRNA and ChAdOx1 vaccineeffectiveness against severe acute respiratory syndrome coronavirus 2,including early variants of concern: a test-negative design, British Columbia,Canada. J Infect Dis. 2022;226(1):485-96. http://doi.org/10.1093/infdis/jiac023

6. Nicolay N, Innocenti F, Beauté J, Ucakar V, Grgic-Vitek M, Poukka E, et al.Initial assessment of the COVID-19 vaccination’s impact on case numbers,hospitalisations and deaths in people aged 80 years and older, 15 EU/EEAcountries, December 2020 to May 2021. Eurosurveillance. 2021;26(48):1-8. http://doi.org/10.2807/1560-7917.ES.2021.26.48.2101030

7. Hippisley-Cox J, Coupland CAC, Mehta N, Keogh RH, Diaz-Ordaz K,Khunti K, et al. Risk prediction of covid-19 related death and hospital admissionin adults after covid-19 vaccination: National prospective cohortstudy. BMJ. 2021:374. https://doi.org/10.1136/bmj.n2244

8. Hyams C, Marlow R, Maseko Z, King J, Ward L, Fox K, et al. Effectivenessof BNT162b2 and ChAdOx1 nCoV-19 COVID-19 vaccination atpreventing hospitalisations in people aged at least 80 years: a test-negative,case-control study. Lancet Infect Dis. 2021;21(11):1539-48. https://doi.org/10.1016/S1473-3099(21)00330-3

9. Chemaitelly H, Yassine HM, Benslimane FM, Al Khatib HA, Tang P, HasanMR, et al. mRNA-1273 COVID-19 vaccine effectiveness against the B.1.1.7and B.1.351 variants and severe COVID-19 disease in Qatar. Nat Med.2021;27:1614-21. https://doi.org/10.1038/s41591-021-01446-y

10. Bautista-Arredondo S, Cerecero-García D, Macías-González F,Barrientos-Gutiérrez T. Supplementary material: The impact of the COVID-19 vaccination policy in Mexico. A quasi-experimental effectivenessevaluation of a multi-vaccine strategy. Harvard Dataverse, 2023. https://doi.org/10.7910/DVN/GPAEEI

11. Comité Nacional para la Vigilancia Epidemiológica. Actualización de laDefinición Operacional de Caso Sospechoso de Enfermedad RespiratoriaViral. Mexico: Gobierno de Mexico, 2020 [cited March 2023]. Availablefrom: https://www.gob.mx/cms/uploads/attachment/file/573732/Comunicado_Oficial_DOC_sospechoso_ERV_240820.pdf

12. Gertler PJ, Martinez S, Premand P, Rawlings LB, Vermeersch CM. Impactevaluation in practice. Washington DC: Inter-American Development Bankand World Bank, 2016. https://doi.org/10.1596/978-1-4648-0779-4

13. Borusyak K, Jaravel X, Spiess J. Revisiting event study designs: Robustand efficient estimation. arXiv Prepr. 2021. https://doi.org/10.48550/arXiv.2108.12419

14. Arregocés-Castillo L, Fernández-Niño J, Rojas-Botero M, Palacios-Clavijo A, Galvis-Pedraza M, Rincón-Medrano L, et al. Effectivenessof COVID-19 vaccines in older adults in Colombia: A retrospective,population-based study of the ESPERANZA cohort. Lancet Heal Longev.2022;3(4):e242-52. http://doi.org/10.1016/S2666-7568(22)00035-6

15. McNamara LA, Wiegand RE, Burke RM, Sharma AJ, Sheppard M,Adjemian J, et al. Estimating the early impact of the US COVID-19vaccination programme on COVID-19 cases, emergency departmentvisits, hospital admissions, and deaths among adults aged 65years and older: An ecological analysis of national surveillance data.Lancet. 2022;399(10320):152-60. https://doi.org/10.1016/S0140-6736(21)02226-1